Local

Pfizer trial: 5-11 year old’s have strong ‘antibody response’ with smaller vaccine dose, doctors say

The first results of the Pfizer COVID-19 vaccine trial in children aged 5 to 11 years are available, and doctors say the data are promising.

Dr. David Conefield, Head of Pediatric Respiratory Medicine at Stanford’s Lucille Packard Children’s Hospital, said:

Dr. Cornfield says strong antibody reactions are attractive.

Related: Pfizer states that the COVID vaccine is safe and effective for children aged 5-11 years

“They hit, so to speak, the’Goldilocks Zone’, where it wasn’t too much, not too little. It was in the right place,” said Dr. Cornfield.

The 2,268 children who participated in the study received two doses at 21-day intervals. Pfizer reduced the dose in this group and gave the children a dose of 10 micrograms. People over the age of 12 usually take a dose of 30 micrograms. Even with this change, Pfizer says it was responsive.

video: Bay Area County is preparing to vaccinate children ages 5-11 prior to Pfizer’s expected approval

“Children’s immune response is often more powerful. It’s more energetic and more powerful if you do so. Therefore, with a little reduction in vaccines, these children will benefit. Not only in terms of antibodies, but also to minimize the negative effects of the vaccine. Minimize inflammation, discomfort, and fever, “says Dr. Cornfield.

This is highly anticipated Presentation, As we see, the kids return to face-to-face class.

according to American Academy of PediatricsSince July, the number of COVID cases in children has increased by about 240% in the United States.

Related: Booster Shot: FDA Advisory Board Hits Biden’s Plan and Rejects Extensive Pfizer Jab

Today, San Francisco parent Melody De Leon said Pfizer’s data gives hope for two daughters, 11-year-old Sophia and 6-year-old Emma, ​​to return to school.

“I was a little relieved because I had the vaccine,” Melody said.

Ironically, on Monday Emma had to stay home because she woke up with a fever.

“The first thing that came to my mind because she had a fever and was vomiting was,’Oh, what’s that? Is it COVID?'” Said Melody.

On Monday, Pfizer announced that it would submit this data before the start of the winter season.

Melody says that time is needed to determine if the daughter is happy to be vaccinated. Sophia says she’s ready.

“I don’t get sick because I want to get vaccinated because you go to places where you don’t know if they have it,” Sophia de Leon said.

Once Pfizer’s data are submitted, FDA officials believe the FDA can vaccinate children aged 5 to 11 years within a few weeks.

Is there a problem loading the above tracker?click here Opens in a new window.

Related articles and videos:

Copyright © 2021 KGO-TV. all rights reserved.



Pfizer trial: 5-11 year old’s have strong ‘antibody response’ with smaller vaccine dose, doctors say Source link Pfizer trial: 5-11 year old’s have strong ‘antibody response’ with smaller vaccine dose, doctors say

Related Articles

Back to top button